An update on optic neuritis

被引:0
作者
Jessica A. Kraker
John J. Chen
机构
[1] Mayo Clinic Hospital,Department of Ophthalmology
[2] Mayo Clinic Hospital,Department of Neurology
来源
Journal of Neurology | 2023年 / 270卷
关键词
Optic neuritis; Neuro-ophthalmology; Multiple sclerosis; Neuromyelitis optica spectrum disorder; MOG antibody-associated disease; Chronic relapsing inflammatory optic neuropathy;
D O I
暂无
中图分类号
学科分类号
摘要
Optic neuritis (ON) is the most common cause of subacute optic neuropathy in young adults. Although most cases of optic neuritis (ON) are classified as typical, meaning idiopathic or associated with multiple sclerosis, there is a growing understanding of atypical forms of optic neuritis such as antibody mediated aquaporin-4 (AQP4)-IgG neuromyelitis optica spectrum disorder (NMOSD) and the recently described entity, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). Differentiating typical ON from atypical ON is important because they have different prognoses and treatments. Findings of atypical ON, including severe vision loss with poor recovery with steroids or steroid dependence, prominent optic disc edema, bilateral vision loss, and childhood or late adult onset, should prompt serologic testing for AQP4-IgG and MOG-IgG. Although the traditional division of typical and atypical ON can be helpful, it should be noted that there can be severe presentations of otherwise typical ON and mild presentations of atypical ON that blur these traditional lines. Rare causes of autoimmune optic neuropathies, such as glial fibrillary acidic protein (GFAP) and collapsin response-mediator protein 5 (CRMP5) autoimmunity also should be considered in patients with bilateral painless optic neuropathy associated with optic disc edema, especially if there are other accompanying suggestive neurologic symptoms/signs. Typical ON usually recovers well without treatment, though recovery may be expedited by steroids. Atypical ON is usually treated with intravenous steroids, and some forms, such as NMOSD, often require plasma exchange for acute attacks and long-term immunosuppressive therapy to prevent relapses. Since treatment is tailored to the cause of the ON, elucidating the etiology of the ON is of the utmost importance.
引用
收藏
页码:5113 / 5126
页数:13
相关论文
共 1724 条
[1]  
Horton L(2018)Acute management of optic neuritis: an evolving paradigm J Neuroophthalmol 38 358-367
[2]  
Bennett JL(1999)Incidence of optic neuritis in Stockholm, Sweden, 1990–1995: II. Time and space patterns Arch Neurol 56 975-980
[3]  
Jin YP(1995)Optic neuritis: a population-based study in Olmsted County, Minnesota Neurology 45 244-250
[4]  
de Pedro-Cuesta J(2017)A population-based prospective study of optic neuritis Mult Scler 23 1893-1901
[5]  
Soderstrom M(2020)Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies Am J Ophthalmol 220 110-114
[6]  
Link H(2008)Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up Arch Neurol 65 727-732
[7]  
Rodriguez M(2018)Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial JAMA Ophthalmol 136 419-422
[8]  
Siva A(2008)Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial Ophthalmology 115 1079-1082.e5
[9]  
Cross SA(2005)Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up J Neurol 252 396-402
[10]  
O’Brien PC(1992)A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group N Engl J Med 326 581-588